User Tools

    To create and edit articles, please register and log-in

Main Menu : categories & index etc.

Main menu
Click categories to expand

A-Z listingplugin-autotooltip__plain plugin-autotooltip_bigA-Z listing

This is an alphabetical index of all content pages.

Other categories



Also see

Importance Ratings
Curator's rationale
AI Policy

Twitter feed 𝕏

Feeds + s.e.o. etc.
rss / xml feed
sitemap file
A-Z listing (archived)

Indexed under : Medicine / Drugs

Wikenigma - an Encyclopedia of Unknowns Wikenigma - an Encyclopedia of the Unknown


Betaxolol - currently sold under brand names Betoptic, Betoptic S, Lokren, Kerlone and others - is a prescription drug used to treat Glaucomaplugin-autotooltip__plain plugin-autotooltip_bigGlaucoma

Glaucoma is a group of eye diseases - the leading cause of non-reversible blindness worldwide. It's linked* with increased intra-ocular pressure (IOP) and results in damage to the retinal cells and the optic nerve. (Note the increased IOP is also sometimes cal…
and its associated ocular hypertension. It was patented in 1975 and was first licenced for medical use over forty years ago.

Its mechanism of action is unknown.

There are no published data detailing the pharmacokinetic properties of betaxolol following ocular administration in humans; such information is important to assess the extent of systemic availability.

Source : Drugs, volume 40, pages 75–90

Also see :Bimatoprostplugin-autotooltip__plain plugin-autotooltip_bigBimatoprost

Bimatoprost is a drug used to treat Glaucoma - linked to excess pressure within the eye. It currently has more than 2 million prescriptions per year in the US alone. Marketed, usually as eye-drops, under the brand names Lumigan, Latisse, Vistitan

    Please share this page to help promote Wikenigma !

Dear reader : Do you have any suggestions for the site's content?

Ideas for new topics, and suggested additions / corrections for older ones, are always welcome.

If you have skills or interests in a particular field, and have suggestions for Wikenigma, get in touch !

Or, if you'd like to become a regular contributor . . . request a login password. Registered users can edit the entire content of the site, and also create new pages.

( The 'Notes for contributors' section in the main menu has further information and guidelines etc.)

Automatic Translation

You are currently viewing an auto-translated version of Wikenigma

Please be aware that no automatic translation engines are 100% accurate, and so the auto-translated content will very probably feature errors and omissions.

Nevertheless, Wikenigma hopes that the translated content will help to attract a wider global audience.

Show another (random) article

Further resources :